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Abstract
Background: Breast cancer (BC) in men is an uncommon disease lacking studies and specific recommendations on clinical guidelines 
focused on this group of patients. During the last years there have been an increase of cases of BC in this subgroup, and some studies 
suggest that differences between both genders.
Objective: To describe a cohort of male patients with BC, to evaluate its clinical characteristics, surgery approach and to review and 
discus critical points on male BC.
Methods: In this cross-sectional study the electronic data was collected retrospectively for the selected cases between April 2010 and 
June 2020. A descriptive analysis of the data and the recurrence Kaplan Meyer curve were performed. 
Results: A total of 19 cases were recorded. The mean age was 65.2 years (±12.6 SD compared with 59.2 years ±16.2 SD in women), 
the Body Mass Index was 28.78 ± 4.9 SD, with 31.6% of cases diagnosed with gynecomastia. In all cases treated with surgery, the 
surgical treatment of choice was mastectomy. The average tumour diameter was 23.58mm. The immunohistochemical subtypes clas-
sification was; Luminal A-like 26.32%, Luminal B-like Her2 negative 52.63%, Luminal B-like Her2 positive 15.79%, Triple negative-
like 5.26%, Her2 pure-like 0%.
Conclusion: The mean age of male BC patients is greater than that observed in women, with a higher rate of luminal histological 
subtypes and a more aggressive surgical approach. Due to being underrepresented or even excluded in most of the studies, today there 
are no-evidence to make the best approach in the management of these patients. 
Keywords: Breast Cancer; Clinical Management; 
Immunohistochemistry; Male Breast Cancer
Introduction
Rationale: Breast cancer (BC) in men is a rare entity, occurring in 
approximately 1% of men and representing between 0.5 and 1% of 
all BC in both genders [1]. For that reason, they are unquestionably 
underrepresented in many of the studies on which the usual 
clinical practice is based. It is noteworthy that at present time we 
do not actually know the optimal management for this subgroup 
of patients with BC, which may differ from the female group. It 
is common to find in clinical guidelines the recommendation to 
treat BC in men as BC in postmenopausal women. In recent years, 
more attention has focused on male BC. According to a recent 
epidemiological study, the incidence and prevalence of this entity 
is increasing significantly [2]. 
It is known that both genders share risk factors such as 
aging, genetic factors and hyper-oestrogenic states such as obesity. 
According to literature, BC in men presents a mean age of onset 
5-10 years later than the women [3]. Regarding genetic risk level, 
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there is an increased risk of developing BC if there is involvement 
of a first-degree relative. Up to 20% of men suffering BC have 
affected first-degree relatives, compared to 7% of the general 
population [3]. Considering risk mutations, men present a different 
pattern than the female gender; being BRCA2 mutation the most 
common found, conferring a 6% absolute risk in life of presenting 
BC [4].
Previous studies document that the most frequent histological 
subtypes are the so-called luminal-like ones, finding rates of 
HER-2 positive tumours of 12.2% and 2.9% of triple negative 
tumours [5]. Despite being mainly the theoretically less aggressive 
subtypes, several studies describe a lower overall survival in BC 
in men compared to BC in women. Possibly, the worst prognosis 
in men may be influenced by the occurrence in older population, 
and the fact BC in men usually occur in more advanced stages [6]. 
Studies specifically aimed at this subpopulation are necessary to 
be able to effectively address the controversies that continue today 
without being resolved. 
Objective: In this case-series and review we aim to describe the 
epidemiological, clinical and pathological characteristics along 
with the treatments received by men complaining with BC in a 
single centre during the last 10 years providing an update on the 
topic.
Material and Methods
A retrospective data collection was made of all cases of BC 
in men diagnosed at Hospital Clínic de Barcelona between 2010 
and 2019.
Sample: Male patients diagnosed with BC between 2010 and 
2019 which were in the electronic health data record of Hospital 
Clínic de Barcelona were included. The cases where information 
regarding clinical, molecular, surgery or histology variables were 
lacking were excluded (Figure 1).
Figure 1: Flowchart diagram of the study.
Design: An observational, cross-sectional, descriptive analysis of the data was performed to assess the epidemiological characteristics 
of patients suffering from this type of cancer, alongside data on clinical variables, imaging tests performed, tumour profile, surgery, 
systemic treatment, pathological anatomy, and the current state of the patient.
Statistical Analysis: The descriptive analysis was performed using the “summarize” and “tabulate” tools. A recurrence descriptive 
analysis was described as a Kaplan Meyer graph. Statistical analysis was made using the statistical program STATA, version 15.1 
(StataCorp) [7]. 
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Results
Study Selection: A total of 19 cases of male patients suffering BC were diagnosed in our center between 2010 and 2019.
Study Findings: Clinical characteristics of the entire sample are given in table 1. Regarding epidemiological characteristics, the mean 
age at diagnosis was 65.2 years (± 12.6 SD) (Age distribution represented on Figure 2), the 31.58% of the patients had been diagnosed 
with gynecomastia, and the mean Body Mass Index (BMI) was 28.78, presenting obesity (defined as a BMI greater than 30) the 30.8% of 
the sample. The prevalence of recreative drugs consumers such as smoking and alcoholic habit greater than or equal to 2 units of alcohol 
daily were 42.1% and 30.0% respectively. No patient reported use of hormonal / anabolic therapies.
Epidemiologic Variables Mean St. Dev. Min Max % (n)
Age 65,21 12,77 42,87 91,38 -
BMI 28,78 4,96 22,60 38,42 -
Alcohol - - - - 31,58 (6)
Tobacco - - - - 42,11 (8)
Histology - - - -
IDC - - - - 89,47 (17)
PC - - - - 5,26 (1)
MDHC - - - - 5,26 (1)
Molecular
ER 85,95 21,89 0 100 -
PR 57,00 36,78 0 100 -
Ki67 24,44 14,11 5 60 -
HER2 positive - - - - 15,79 (3)
Immunohistology subtypes
Luminal A like - - - - 26,32 (5)
Luminal B HER2 positive like - - - - 15,79 (3)
Luminal B HER2 negative like - - - - 52,63 (10)
HER2 enriched like - - - - 0
TN like - - - - 5,26 (1)
Table 1: Descriptive analysis of study variables. St. Dev.: Standard Deviation, BMI: Body Mass Index, IDC: infiltrating ductal carcinoma, 
PC: papillary carcinoma, MDHC: moderately differentiated hydro-carcinoma, ER: estrogen receptors, PR: progesterone receptors, TN: 
Triple negative.
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Figure 2: Age at diagnosis for the 19 cases reported.
Concerning diagnostic variables, in a 41.11% of cases 
affected the left breast (8), in 52.63% the right breast (10), and 
in one case was bilateral. The mean tumour size at diagnosis was 
23.58 mm and 21.05% of patients presented confirmed axillary-
positive lymph node by Fine Needle Aspiration (FNA) after 
ultrasound suspicion of locoregional metastasis. In 18 patients 
(94.74%) BC was unifocal, being multifocal BC only in one case. 
The clinical BC stage prior to surgery were: Stage I in 20% of 
cases, Stage II in 46.67%, Stage III in 26.67% and Stage IV in the 
remaining 6.67%.
In 13 cases (68.42%), treatment started with primary 
surgery, and mastectomy was performed in 100% of our cases. 
Six of the cases underwent systemic neoadjuvant treatment 
(31.58%). Holding on axillary surgery, selective sentinel node 
biopsy (SSNB) was performed in 16 of cases (84.21%). Three 
of the SSNB obtained were positive), completing the following 
lymphadenectomy in all cases. Lymphadenectomy was performed 
in 5 of total cases (2 directly, 3 after SSNB result) and one patient 
did not receive axillary surgery.
Analyzing the 4 positive FNA cases at baseline, one did not 
perform treatment due to the finding of metastases, and another 
case received neoadjuvant therapy, and subsequent SSNB and 
lymphadenectomy were negative.
Focusing on the pathology, 89.47% were classified as 
infiltrating ductal carcinoma, 5.26% as papillary carcinoma 
and 5.26% as moderately differentiated hydro-carcinoma. The 
histological grade was classified as grade II for 94.74% of the 
cases, by 5.26% of grade I and no cases classified as grade III.
Examining molecular variables, 15.79% cases were found 
positive for HER2 receptors, 85.95% positive for estrogen 
receptors, 57.00% positive for progesterone receptors, and the 
Ki67 presented an average of 24.44%. The tumours were classified 
into immunohistochemical subtypes; Luminal A 26.42%, Luminal 
B Her2 negative 52.63%, Luminal B Her2 positive 15.79%, Triple 
negative 5.26%. No patients showed the subtype Her2 enriched.
The PROSIGNA genetic test was performed in 26.3% of 
cases, obtaining 40% of Luminal A and 60% of Luminal B. A study 
of mutations was carried out in 57.89% of patients, presenting 
one case of BRCA1 mutation, one case of BRCA2 mutation and 
another unique case of CHECK2 mutation.
Finally, the 15.8% of the cohort received adjuvant 
radiotherapy, 73.68% of the patients received chemotherapy 
(neoadjuvant in 31.58%) and 68.42% received tamoxifen (single 
systemic therapy in 23.5%). Recurrence or decease was observed 
in 36.6% of the patients during a 10-year follow-up. The mean 
survival / free of disease time was 58.89 months (Standard Error 
6.02) (Figure 3). 
Figure 3: Kaplan Meyer Recurrence curve estimate in months.
Discussion
Male breast cancer is considered a rare disease. Due to the 
high incidence of BC in women, the few cases that appear in the 
opposite gender are dissolved or directly excluded in many of the 
studies that are carried out. Most of the guidelines recommend 
treating BC equally in both sexes, since there is no specific 
scientific evidence for this subpopulation.
The main risk factor described in literature is aging. It has 
been reported a mean age of onset of 68.4 years for BC in men [8], 
higher than that reported in women of about 62 years of age [9,10]. 
In our population during the study period, the mean age at diagnosis 
was greater than 65 years in men compared to a mean age of 59.3 
years (± SD 16.2) in women (data not shown). The risk presented 
by obese patients must also be taken into account, since due to 
the transformation of androgens to oestrogens in adipose tissue, 
the lower concentration of testosterone and sex hormone-binding 
globulin, they usually present hyper-oestrogenic states capable of 
stimulate breast tissue [11]. Related to hyper-oestrogenism we find 
gynecomastia, a disorder that occurs in up to 70% of men over 
50 years of age [12]. Studies show that the risk of atypical ductal 
hyperplasia is between 0.4 % to 5.4%, not finding data on the risk 
of BC in men suffering from gynecomastia [13].
The series of patients described in the literature agree that the 
luminal histological subtypes are by far the most frequently found 
in BC in men. In our data series we also found this characteristic in 
more than 80% of cases, despite being lower than the data found 
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in articles that compare the characteristics of BC between both 
genders. The low prevalence of Her-2 enriched cases is striking, 
no cases in our series, and 0.6% of cases according to Leone et al 
in their recent publication [14].
When comparing the survival between BC in men to BC 
in females, the literature agree that the male subgroup presents a 
decreased overall survival. There are different theories to justify 
this worse prognosis. We know that males present a higher 
percentage of luminal-like type histological subtypes, so we would 
think that they may suffer from relatively less aggressive tumours. 
However, it is more common to find advanced stages at diagnosis, 
presenting up to 20% of positive axillary nodes. Some studies 
show that in reality the survival when comparing between men and 
women suffering BC in Stages III and IV is similar, but a worse 
prognosis in males have been found in Stages I and II at diagnosis 
compared to females [14].
In our series we describe that up to 33% of cases are diagnosed 
in advanced stages, with 21% of N1 cases being diagnosed. To 
date, 36% of cases have had a recurrence or died on a 10-year-
follow up after diagnosing, suggesting a worse prognosis compared 
to female patients diagnosed with BC [15]. This increased risk 
does not seem to be due to the diagnosis in higher stages, nor to 
histological subtypes with a worse prognosis [16]. Larger studies 
are needed, specifically aimed at this population, to study if there 
are biological factors that grant this increased risk per se.
Finally, it is worth discussing whether we could reduce 
the diagnosis in advanced stages with better diagnostic tools, or 
information for this population group. We do not have data, but it 
could be that we are dealing with cases which had a late diagnosis 
due to the low suspicion of BC in men, which would mean that 
cases of breast tumours in men were not prioritized.
According to the literature and our data, due to a smaller 
breast size in men, the most common surgery is mastectomy 
(100% of the cases in our series) [17]. There is a new trend to try 
to be less aggressive if the tumour size allows us to try to maintain 
more favourable cosmetic results, and even offer reconstruction 
with oncoplastic techniques [18]. 
The exposed paper present various limitations. Given that 
BC is a rare disease in males, it is difficult to obtain cohorts of 
patients with large sizes, so the N of patients obtained may be a 
limitation when drawing conclusions from the data.
When performing a cross-sectional and retrospective study, 
any correlation of variables found may be due to the biases inherent 
in this type of study.
Conclusion
We conclude that in our case series we have a mean age of 
male patients greater than in females. Men with BC have in general 
a worse prognosis despite presenting less aggressive histological 
subtypes. This may be due to a possible diagnostic delay, finding 
up to 33% of cases with advanced stages. Moreover, BC in men 
is treated using a more aggressive surgical approach, presenting a 
100% of cases treated with mastectomy in our series.
Due to being underrepresented or even excluded in most 
studies regarding the treatment of breast cancer, today we do 
not have clear evidence to make the best clinical decisions in the 
subgroup of men with BC. More studies directed at this population 
are required to study possible unknown biological risks, in addition 
to studies to assess de-escalation of the type of surgery performed 
in these patients, since despite presenting small tumours in some 
cases, the usual treatment continues to be mastectomy.
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